{
  "source": "PubMed",
  "query": "stilbenes",
  "title": "Differential benefit of adjuvant everolimus according to endocrine therapy backbone in the randomized UNIRAD trial.",
  "abstract": "The randomized, double-blind UNIRAD trial evaluating the addition of 2 years of everolimus to endocrine therapy in patients with high-risk, early luminal breast cancer failed to demonstrate a benefit. We report the subgroup analyses.",
  "publication_date": "2025-04-15",
  "journal": "ESMO open",
  "doi": "10.1016/j.esmoop.2025.105050"
}